Revenues rose 16.6% to €2.32bn, driven by the Bormioli Pharma acquisition, but profitability declined due to impairments, exceptional items, and higher costs, resulting in a net loss of €318.7m. Liquidity and refinancing risks remain elevated, with future performance hinging on the Centor Inc. sale and transformation program execution.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.